Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery

Head and Neck

Volumn 35, Issue 10, 2013, Pages 1499-1506

  Mehta, Vikas ^a   Nikiforov, Yuri E ^b   Ferris, Robert L ^a  

^a University of Pittsburgh School of Medicine   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

biomarkers; diagnosis; molecular testing; prognosis; Thyroid

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CARCINOMA IN SITU; CASE REPORT; CLINICAL DECISION MAKING; CYTODIAGNOSIS; CYTOLOGY; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MALE; METASTASIS POTENTIAL; MOLECULAR DIAGNOSIS; MORTALITY; NECK DISSECTION; ONCOGENE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR DIFFERENTIATION; TUMOR VOLUME;

BIOMARKERS; DIAGNOSIS; MOLECULAR TESTING; PROGNOSIS; THYROID;

ADULT; AGED; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROID NODULE; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84884902768     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23140     Document Type: Article

References (37)

1. Hamberger B, Gharib H, Melton LJ III, Goellner JR, Zinsmeister AR,. Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med 1982; 73: 381-384.
2. Wang CC, Friedman L, Kennedy GC, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid 2011; 21: 243-245.
3. Lewis CM, Chang KP, Pitman M, et al. Thyroid fine-needle aspiration biopsy: variability in reporting. Thyroid 2009; 19: 717-722.
4. Hegedus L,. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351: 1764-1771.
5. Layfield LJ, Cibas ES, Gharib H, Mandel SJ,. Post-FNA management for diagnostic categories. Thyroid aspiration cytology: current status. CA Cancer J Clin 2009; 59: 99-110.
6. Mowatt G, Zhu S, Kilonzo M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010; 14: 1-331.
7. Blank PR, Schwenkglenks M, Moch H, et al. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res Treat 2010; 124: 497-507.
8. Nikiforova MN, Nikiforov YE,. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009; 19: 1351-1361.
9. - targeting to the membrane. Endocr Relat Cancer 2006; 13: 257-269.
10. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92: 2840-2843.
11. Xing M,. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-262.
12. Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL, Asa SL,. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 1996; 6: 409-416.
13. Downward J,. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
14. Tallini G, Asa SL,. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 2001; 8: 345-354.
15. Kondo T, Ezzat S, Asa SL,. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6: 292-306.
16. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA,. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997; 57: 1690-1694.
17. Rabes HM, Demidchik EP, Sidorow JD, et al. Pattern of radiation- induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 2000; 6: 1093-1103.
18. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM,. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 2000; 85: 1170-1175.
19. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006; 30: 216-222.
20. Kroll TG, Sarraf P, Pecciarini L, et al. PAX 8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000; 289: 1357-1360.
21. Eberhardt NL, Grebe SK, McIver B, Reddi HV,. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol 2010; 321: 50-56.
22. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003; 88: 2318-2326.
23. Chung KW, Yang SK, Lee GK, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol 2006; 65: 660-666.
24. Mathur A, Weng J, Moses W, et al. A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery 2010; 148: 1170-1176.
25. Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL,. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 2001; 86: 2187-2190.
26. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96: 3390-3397.
27. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93: 3943-3949.
28. Rodolico V, Cabibi D, Pizzolanti G, et al. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid < or = 1 cm and their paired lymph node metastases. Cancer 2007; 110: 1218-1226.
29. Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009; 16: 240-245.
30. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 4085-4090.
31. Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 2012; 118: 2069-2077.
32. Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL,. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 1994; 116: 1010-1016.
33. Soares P, Fonseca E, Wynford-Thomas D, Sobrinho-Simoes M,. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol 1998; 185: 71-78.
34. Teixeira GV, Chikota H, Teixeira T, Manfro G, Pai SI, Tufano RP,. Incidence of malignancy in thyroid nodules determined to be follicular lesions of undetermined significance on fine-needle aspiration. World J Surg 2012; 36: 69-74.
35. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance." Cancer Cytopathol 2010; 118: 17-23.
36. Yip L, Farris C, Kabaker AS, et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab 2012; 97: 1905-1912.
37. Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW,. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2011; 6: E1719-E1726.